Can Oxford Nanopore and Lonza fix the mRNA quality control bottleneck?
Find out how Oxford Nanopore and Lonza’s GMP mRNA QC solution could simplify release testing for next-generation RNA medicines.
Pharma & Biotech
Pharma & Biotech
Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.
Features & Analysis
Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms
Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.
Medical Devices & Diagnostics
Can Elmach’s WKH-100 cartoner help pharma manufacturers rethink compact packaging automation?
Find out how Elmach’s WKH-100 cartoner could improve flexible, GMP-ready pharma packaging for bottles, blisters and tubes.
Pharma & Biotech
Can United Immunity revive macrophage cell therapy after Carisma’s reset?
Macrophage cell therapy has promise but painful execution risk. United Immunity’s Carisma deal tests whether in vivo CAR-M can scale.
Pharma & Biotech
Lupin just cracked China with a flu drug. Why investors may want to look closer
Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.
Pharma & Biotech
Can Niowave’s Michigan facility ease the Actinium-225 bottleneck in cancer therapy?
Find out how Niowave’s $75m Michigan facility could reshape Actinium-225 supply for targeted cancer therapies.
Features & Analysis
Can emergency Ebola treatment centers close Africa’s outbreak response gap?
Find out how Samaritan’s Purse’s Ebola treatment deployment in Congo highlights urgent gaps in outbreak readiness and field care.
Medical Devices & Diagnostics
Why Basler’s embedded vision system matters for next-generation laboratory automation
Find out how Basler’s GMSL vision system could improve lab automation, imaging workflows, and data handling in life sciences.
Features & Analysis
A rare disease policy shift just landed at the WHO. Could it change hemophilia care worldwide?
Find out how the WHO hemophilia resolution could reshape diagnosis, treatment access, prophylaxis and bleeding disorder care worldwide.